Estée Lauder's Turnaround: Offloading Dr. Jart, Too Faced, and Smashbox

The Divestment Strategy

Estée Lauder's portfolio has become unwieldy. Under previous leadership, the company acquired aggressively—Dr. Jart+ (2007, acquired as part of a larger deal), Too Faced (2016), Smashbox (2012), Becca (2013). The strategy was portfolio diversification: capture millennial/Gen Z consumer trends, expand price points, build category presence across color cosmetics, skincare, and prestige.

The result: a bloated portfolio lacking cohesion. Dr. Jart+ sold $456M in 2025 revenue but operated at margin compression due to discounting wars with Amazon and Sephora. Too Faced generated approximately $320M annually but suffered from founder absence (Jerrod Blandino exited creative direction in 2019) and brand identity erosion. Smashbox, a once-vibrant makeup brand, declined to approximately $180M in revenue with minimal growth trajectory.

De la Faverie's analysis was straightforward: these brands consume capital, managerial attention, and operational resources with insufficient return. For a publicly traded company facing investor pressure on margins and cash flow, the math favors liquidation.

Dr. Jart+ is the most significant divestment. The K-Beauty-adjacent skincare brand generated over $450M in 2025 revenue, but in a margin-compressed market. The company's acquisition by private equity (Advent Partners and Permira have expressed interest) is expected to fetch $900M-1.2B, representing a modest multiple on revenue but a psychological win for Lauder—shedding a non-core asset and redeploying capital.

Repricing and Portfolio Consolidation

De la Faverie's second lever: repricing legacy franchises. MAC Studio Fix (the iconic powder foundation) is being repositioned from $45 to $35, breaking a 12-year pricing model. This controversial move signals margin defense through volume growth rather than ASP maintenance—a departure from legacy Lauder strategy.

Advanced Night Repair, the company's flagship skincare franchise, is being reformulated with PDRN and peptides to compete against K-Beauty innovation at comparable price points. The message: Lauder won't cede premium skincare to Korean competitors; it will repurpose its distribution and retail relationships to offer competitive formulations at prestige pricing.

Clinique, historically positioned as prestige-adjacent, is being rebranded as accessible luxury—shifting from $68 moisturizers to $42-58 options, attempting to compete with Cerave and Neutrogena's prestige positioning while maintaining Sephora distribution advantages. The implicit admission: Clinique's heritage isn't sufficient to justify 2025 pricing. Value and efficacy must compete.

The Pat McGrath Labs Question

The most strategic uncertainty: Pat McGrath Labs. Lauder acquired the makeup artist-founded brand in 2018 for a reported $1.2B (valuing it at the highest beauty acquisition multiple ever recorded at the time). The brand generated approximately $320M in annual revenue in its peak (2021-2022), has declined modestly to $285M in 2025.

PMG is simultaneously Lauder's greatest achievement (founder-led, culturally credible, DTC-native) and its greatest vulnerability (high acquisition cost, founder dependency). Reports indicate Lauder is exploring strategic options: maintain, divest to private equity, or restructure founder arrangements. A sale would be psychologically damaging (admitting acquisition failure), but capital deployment to higher-return divisions might justify liquidation.

De la Faverie has publicly stated "all non-core assets are under review," which includes PMG. If divested, the brand might fetch $800M-1.1B (assuming 2.8-3.9x revenue multiple), allowing Lauder to redeploy $350M-500M in cash and reduce founder-brand execution risk. Conversely, maintaining PMG signals confidence in founder reinvention and DTC-driven growth.

Job Cuts and Operational Efficiency

In January 2026, Lauder announced a global workforce reduction of 3-5%, affecting approximately 2,100-3,500 employees across corporate, brand, and distribution functions. The cuts target corporate overhead (reduced from 17% to 12% of total headcount) and consolidate support functions across divested brands.

The efficiency target: reduce operating costs by $280M-350M annually by 2027. This funds repricing, innovation investment, and shareholder returns without revenue growth dependence. It's a defensive strategy, but executed aggressively.

The Bigger Picture: Legacy Beauty Under Pressure

Estée Lauder's turnaround reflects a broader legacy beauty challenge: conglomerates built on distribution and scale are structurally disadvantaged against digital-native, founder-led, innovation-forward competitors. When consumers can access K-Beauty directly (via Sephora, Yesstyle, Amazon), prestige positioning alone doesn't justify premium pricing.

De la Faverie's strategy implicitly accepts this: Lauder won't fight K-Beauty or indie beauty on innovation. Instead, it will leverage distribution, retail relationships, and heritage to capture margin at mid-prestige positioning. Reprice down, consolidate portfolio, operate efficiently, divest non-core assets, and return cash to shareholders.

It's not a growth story. It's a managed decline with improved returns—a rational choice for a $18B market cap company facing innovation disruption and margin compression. By 2028, Estée Lauder will likely operate 6-8 major brands (Estée Lauder, Clinique, MAC, Aramis, La Mer, Origins, and potentially PMG and one additional prestige acquisition) rather than the current 15+. The company will be leaner, more focused, and potentially more profitable—but undeniably less innovative and culturally relevant than competitors investing in K-Beauty, indie brands, and biotech skincare innovation.